Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 2
2005 4
2006 2
2007 3
2008 1
2009 4
2010 6
2011 8
2012 5
2013 1
2014 2
2015 4
2016 9
2017 6
2018 5
2019 3
2020 8
2021 8
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Okajima D, et al. Among authors: yamaguchi m. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. doi: 10.1158/1535-7163.MCT-21-0206. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413126 Free PMC article.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Saura C, et al. Among authors: yamaguchi m. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. J Clin Oncol. 2020. PMID: 32678716 Free PMC article. Clinical Trial.
Histopathology of non-mass-like breast lesions on ultrasound.
Yamaguchi R, Watanabe H, Mihara Y, Yamaguchi M, Tanaka M. Yamaguchi R, et al. Among authors: yamaguchi m. J Med Ultrason (2001). 2023 Jul;50(3):375-380. doi: 10.1007/s10396-023-01286-y. Epub 2023 Feb 11. J Med Ultrason (2001). 2023. PMID: 36773105 Free PMC article. Review.
Pericyte-myofibroblast transition in the human lung.
Yamaguchi M, Hirai S, Tanaka Y, Sumi T, Tada M, Takahashi H, Watanabe A, Sakuma Y. Yamaguchi M, et al. Biochem Biophys Res Commun. 2020 Jul 23;528(2):269-275. doi: 10.1016/j.bbrc.2020.05.091. Epub 2020 May 27. Biochem Biophys Res Commun. 2020. PMID: 32473754
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Kiga Y, Izutani T, Shiosakai K, Tsurutani J. Niikura N, et al. Among authors: yamaguchi m. NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5. NPJ Breast Cancer. 2023. PMID: 37821514 Free PMC article.
ER staining levels affect HER2 staining and heterogeneity.
Akashi M, Yamaguchi R, Kusano H, Yamaguchi M, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H. Akashi M, et al. Among authors: yamaguchi m. Breast Cancer. 2021 May;28(3):720-726. doi: 10.1007/s12282-020-01208-7. Epub 2021 Jan 9. Breast Cancer. 2021. PMID: 33423217
90 results